Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT04948411
- Lead Sponsor
- Latin American Cooperative Oncology Group
- Brief Summary
Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- Patients with unresectable stage III NSCLC who completed a platinum-based chemotherapy concurrently or sequentially with radiation therapy without evidence of disease progression
- Patients who have participated in the Durvalumab EAP in Brazil and have received at least one dose of Durvalumab in the EAP..
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Describe real world data on PFS of patients treated with Durvalumab in stage III NSCLC in the EAP in Brazil June of 2018
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Núcleo de Oncologia da Bahia S.A
🇧🇷Salvador, Bahia, Brazil
Instituto Mário Penna
🇧🇷Belo Horizonte, Minas Gerais, Brazil
Sociedade Beneficente de Senhoras Hospital Sírio-Libanês
🇧🇷São Paulo, Brazil
BP - A Beneficência Portuguesa de São Paulo
🇧🇷São Paulo, Brazil